<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476541</url>
  </required_header>
  <id_info>
    <org_study_id>NOPHO-AML 2004</org_study_id>
    <nct_id>NCT00476541</nct_id>
  </id_info>
  <brief_title>NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia</brief_title>
  <official_title>NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to improve the cure rate of children with newly diagnosed acute
      myeloid leukemia (AML) who undergo risk-adapted therapy.

      Stem cell transplantation (SCT) is reserved to high-risk patients defined by cytogenetics and
      response to chemotherapy. The efficacy and toxicity of Gemtuzumab ozogamicin (GO, Mylotarg)
      will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective is to improve the cure rate of pediatric patients with newly diagnosed
      acute myeloid leukemia (AML). The specific aims are as follows:

      1.1 Therapeutic aims

      To improve the event-free survival (EFS) of AML patients who undergo risk-adapted therapy.

      To improve the overall survival (OS) by reserving stem cell transplantation (SCT) to
      high-risk patients based on cytogenetics and response to induction therapy.

      To compare the outcome of SCT using HLA-matched sibling donor (MSD) or HLA-matched unrelated
      donor (MUD).

      To assess the efficacy and toxicity of Gemtuzumab ozogamicin (GO, Mylotarg) as post
      consolidation therapy.

      1.2 Biologic aims

      To study minimal residual disease (MRD) levels in blood and bone marrow (BM) at defined time
      points and to study the prognostic impact of MRD.

      To test in vitro cellular drug resistance at diagnosis and relapse, and correlate these data
      to background factors and clinical outcome.

      To secure storage of biological material from diagnosis for future biologic studies
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemtuzumab 5 mg / m2 two courses with three week interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No further therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab ozogamicin</intervention_name>
    <description>Two courses of Gemtuzumab vs. no further therapy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mylotarg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML as defined by the diagnostic criteria,

          -  Age &lt; 19 years at time of study entry,

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemo- or radiotherapy,

          -  AML secondary to previous bone marrow failure syndrome,

          -  Down syndrome (DS),

          -  Acute promyelocytic leukemia (APL),

          -  Juvenile myelomonocytic leukemia (JMML),

          -  Myelodysplastic syndrome (MDS),

          -  Fanconi anemia,

          -  Positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Hasle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, Aarhus University Hospital Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.nopho.org</url>
    <description>Official website of NOPHO</description>
  </link>
  <reference>
    <citation>Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Zeller B, Gustafsson G; Nordic Society of Pediatric Hematology and Oncology (NOPHO); AML Study Group. Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials. Leukemia. 2005 Dec;19(12):2090-100.</citation>
    <PMID>16304571</PMID>
  </reference>
  <reference>
    <citation>Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Gustafsson G. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol. 2003 Jul;122(2):217-25.</citation>
    <PMID>12846889</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Children</keyword>
  <keyword>Gemtuzumab ozogamicin</keyword>
  <keyword>Stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

